Talking Multiple Myeloma: Strategies to Treat and Manage Patients in the Frontline and Beyond

Friday, September 16, 2022, 8:00 AM - Thursday, August 31, 2023, 11:59 PM, Online Course, Cincinnati, OH

AMA PRA Category 1 Credits™ (1.00 hours), AMA PRA Category 1 Credits™ Designated (1.00 hours)

Talking Multiple Myeloma highlights recent advances in the initial management of multiple myeloma. Through patient cases and scenarios, the expert faculty presenters will guide the integration of new evidence into clinical treatment paradigms of newly diagnosed multiple myeloma.

There are no fees for participating in and receiving CME credit for this online activity.

Click 'register now' to access this activity.

1. Review the latest guidelines for the treatment and management of multiple myeloma (MM);
2. Deliberate on the emerging standard of care for frontline therapy;
3. Evaluate the safety and efficacy of triplet and quadruplet combinations in early lines of therapy in MM;
4. Identify goals, administration preferences, duration, and endpoints to individualize frontline therapy for diverse patients with MM
5. Discuss strategies for maintenance and further sequencing therapy in MM

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and Practice Point Communications. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

Physician Assistants (AAPA), Nurse Practitioners (AANP), and Nurses (ANCC) can count ACCME activities certified for AMA PRA Category 1 Credit™ for professional credit reporting purposes. All healthcare professionals, other than physicians, should inquire with their respective certifying or licensing boards to confirm.

Disclosure of Ineligible Relationships (COI) Policy

In accordance with the ACCME Standards for Integrity and Independence and the University of Cincinnati policy, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies (commercial interest) within the last 24-months. The ACCME requires us to disqualify individuals who refuse to provide this information from involvement in the planning and implementation of accredited continuing education. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence.

The faculty and planners reported the following financial relationships, or relationships to products or devices, they have with ineligible companies (commercial interests) related to the content of this CME activity. The noted relationships below have been mitigated and not relevant to this presentation.

PLANNING COMMITTEE DISCLOSURES

Practice Point Communications

Nirupama Mulherkar
Martin Stevens
Jill Valone

University of Cincinnati

Robert Ellis, MD
Susan Tyler, PhD
Heather Muskopf

The University of Cincinnati and Practice Point Communications and the peer/content reviewers for this activity have no relationships to disclose.

Disclaimer Statement
The opinions expressed during this educational activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati or Practice Point Communications. The information is presented for the purpose of advancing the attendees’ professional development.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Neither the University of Cincinnati nor CORE Medical Education, LLC, recommends the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Learner Assurance Statement
The University of Cincinnati is committed to mitigating all conflicts of interest issues that could arise as a result of prospective faculty members’ relationships with ineligible companies. The University of Cincinnati is committed to retaining only those speakers with financial interests that can be mitigated as they relate to the goals and educational integrity of the CME activity.

Disclosure of Ineligible Relationships (COI) Policy

In accordance with the ACCME Standards for Integrity and Independence and the University of Cincinnati policy, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies (commercial interest) within the last 24-months. The ACCME requires us to disqualify individuals who refuse to provide this information from involvement in the planning and implementation of accredited continuing education. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence.

The faculty and planners reported the following financial relationships, or relationships to products or devices, they have with ineligible companies (commercial interests) related to the content of this CME activity. The noted relationships below have been mitigated and not relevant to this presentation.

Faculty Disclosures

Andrew Cowan, MD
Associate Professor Medicine
University of Washington
Seattle, Washington

Research Grants/Investigator: AbbVie, Adaptive, Celgene/BMS, Harpoon, Janssen, Nektar Therapeutics, Sanofi
Consultant: AbbVie, Celgene/BMS, GlaxoSmithKline, GUSA, Janssen, Secura Bio

Nina Shah, MD
Professor of Clinical Medicine
University of California San Francisco

Advisory Committee/ Board: Amgen, GlaxoSmithKline, Indapta Therapeutics, Sanofi
Research Grants/ Investigator: Bluebird Bio, Celgene/BMS, Janssen

Mitigation of Relevant Financial Relationships

The University of Cincinnati adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests) over the last 24-months. All relevant relationships have been mitigated prior to the commencement of the activity.

Information regarding the new updated ACCME Standards for Integrity and Independence in Accredited Continuing Education can be found on the ACCME website.

This educational activity is supported by an educational grant from Bristol Myers Squibb and Janssen Scientific Affairs, LLC.